| Project/Area Number |
20790926
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Research Institute, Shiga Medical Center |
|---|
Principal Investigator |
KAGAWA Shinya Research Institute, Shiga Medical Center, 主任研究員 (10393191)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 上皮成長因子 / PET / 画像診断 / 癌 / 分子標的 / PET画像診断 / 国際情報交換 / アメリカ / 上皮成長因子素 |
|---|
| Research Abstract |
The purpose of this study is to assess the efficacy of I-mIPQA PET imaging for prediction of responsiveness to therapy with EGFR kinase inhibitor gefitinib with orthotopic non-small cell lung carcinoma xenograft in mice. Human lung carcinoma cells PC14GL, H441GL, H3255GL, and H1975GL, expressing different EGFR mutants and various levels of TGFα. In vitro uptake study of I-mIPQA with these lung cancer cell lines, biodistribution study of I-mIPQA in tumor bearing mice with or without inhibitor were performed. I-mIPQA PET imaging: 3 and 24 hours imaging post intravenous injection of radiotracer using microPET were also conducted followed by auroradiograpfy (ARG) study of I-mIPQA after PET imaging with or without treatment with Gefitinib (Iressa), for three days after PET imaging. PET with I-mIPQA would be a promising molecular imaging of different EGFR kinase mutant NSCL carcinomas for prediction of responsiveness to EGFR Kinase inhibitors in patients.
|
